Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm

FDA postpones Feb. 13 advisory committee review of heart failure drug due to “unanticipated weather conditions” expected for the Washington, D.C. area, although the cardio-renal panel’s meeting on The Medicines Co.’s cangrelor will proceed as planned Feb. 12.